NeurologyLive Year in Review: Top FDA Approvals
The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments for Parkinson disease and epilepsy.
US Food and Drug Administration
2019 has been a monumental year for new therapies for neurologic diseases. From migraine to MS, the FDA has approved numerous new treatments to address unmet needs in a range of disorders, including the first ever gene therapy for spinal muscular atrophy, as well as the first drug approved for episodic cluster headache.
The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments and improve time to treatment effect in conditions like Parkinson disease and epilepsy.
Look back on some of the most signficant FDA approvals in 2019 through the links below:
Istradefylline - Parkinson Disease
Eculizumab - Neuromyelitis Optica Spectrum Disorder
Cenobamate - Partial-Onset Seizures
Riluzole Oral Film - Amyotrophic Lateral Sclerosis
Cladribine - Multiple Sclerosis
Midazolam Nasal Spray - Seizure Clusters
Zolgensma - Spinal Muscular Atrophy
Galcanezumab - Episodic Cluster Headache
Golodirsen - Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Solriamfetol - Excessive Daytime Sleepiness in Narcolepsy, Obstructive Sleep Apnea
Diroximel Fumarate - Relapsing MS, Clinically Isolated Syndrome
